

Catalog No.

Stent Length	Stent Diameter						
	2.25mm	2.5mm	2.75mm	3.0mm	3.25mm	3.5mm	4.0mm
8mm	1500225-08	1500250-08	1500275-08	1500300-08	1500325-08	1500350-08	1500400-08
12mm	1500225-12	1500250-12	1500275-12	1500300-12	1500325-12	1500350-12	1500400-12
15mm	1500225-15	1500250-15	1500275-15	1500300-15	1500325-15	1500350-15	1500400-15
18mm	1500225-18	1500250-18	1500275-18	1500300-18	1500325-18	1500350-18	1500400-18
23mm	1500225-23	1500250-23	1500275-23	1500300-23	1500325-23	1500350-23	1500400-23
28mm	1500225-28	1500250-28	1500275-28	1500300-28	1500325-28	1500350-28	1500400-28
33mm	1500225-33	1500250-33	1500275-33	1500300-33	1500325-33	1500350-33	1500400-33
38mm	1500225-38	1500250-38	1500275-38	1500300-38	1500325-38	1500350-38	1500400-38

Compliance Chart

PRESSURE (atm)	2.25mm	2.5mm	2.75mm	3.0mm	3.25mm	3.5mm	4.0mm
8	2.27	2.53	2.60	2.79	2.98	3.36	3.74
9	2.31	2.58	2.66	2.86	3.05	3.42	3.82
10	2.35	2.63	2.71	2.91	3.11	3.47	3.89
11	2.39	2.67	2.75	2.96	3.17	3.52	3.95
12	2.42	2.71	2.79	3.00	3.22	3.56	4.01
13	2.45	2.74	2.82	3.04	3.26	3.59	4.05
14	2.48	2.77	2.86	3.07	3.30	3.63	4.10
15	2.51	2.80	2.88	3.10	3.33	3.66	4.14
16	2.53	2.83	2.91	3.13	3.37	3.70	4.18
17	2.56	2.85	2.94	3.16	3.40	3.73	4.22
18	2.58	2.88	2.97	3.19	3.43	3.77	4.26
19	2.60	2.91	3.00	3.21	3.46	3.81	4.29
20	2.63	2.94	3.03	3.24	3.50	3.84	4.34
Max expansion diameter	3.75mm					5.5mm	

■ Rated Burst Pressure (RBP) ■ NP

Do not operate in the case of pressure exceeding Rated Burst Pressure (RBP) or expansion exceeding 3.75mm (diameter 2.25 – 3.25mm), or expansion exceeding 5.5mm (diameter 3.5mm and 4.0mm). These nominal data are based on in Vitro tests and did not consider resistance of lesions. Completely expand the stent and check the diameter of the stent with angiography.

Stent Specifications

Stent Material	L-605 Cobalt Chrome	Drug Dose	100µg/cm ²	Strut Thickness	0.0032"
Drug	Everolimus	Polymer	fluoropolymer		

5F, Samtan B/D, Gangnam-gu, 421 Youngdongdaero, Abbott Vascular Korea, Seoul, Korea
Unless otherwise specified, all product and service names appearing herein are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
No use of any Abbott trademark, trade name, or trade dress may be made without the prior written authorization of Abbott.

XIENCE Sierra is a trademark of the Abbott Group of Companies.
© 2018 Abbott. KR CP0063-EN 11/18. All Rights Reserved.



Xience
Sierra
Slim, but Bigger



XIENCE Sierra Slim, but Bigger



UNIQUELY DESIGNED TO POST-DILATE TO 5.5 mm¹

As Cell Length and Bar-Arm are longer, max expansion diameter and the cell expansion has increased.


Stent platform (3.5 and 4.0mm)

Longer Bar-Arm leads to the longer max expansion diameter of the stent.

NEW

Longer Cell Length leads to the bigger cell expansion.


NEW



XIENCE Sierra
XIENCE Alpine

5.5mm

Maximum expansion for 3.5 mm and 4.0 mm



0.0%
shortening

XIENCE Sierra

Zero shortening event at max expansion to 5.5mm


Ultra low stent crossing profile²

Improved design of the stent has accomplished a thinner stent profile than XIENCE Alpine, resulting in a decrease in friction with the blood vessel and easy stent delivery.

Stent platform (2.25~3.25mm)

Optimized MULTI-LINK stent design allows for the tighter crimping and smoother crossing

NEW



XIENCE Sierra
XIENCE Alpine

Catheter Component

	Catheter Technology	Balloon	Stent Design and Material	Drug / Dose	Polymer
XIENCE Alpine	XIENCE Alpine Catheter	Multi-Layer Balloon	MULTI-LINK 8 Cobalt Chromium	Everolimus 100 µg/cm ²	Fluoropolymer
XIENCE Sierra	NEW XIENCE Sierra Catheter	NEW Thinner Balloon	NEW Sierra Platform Cobalt Chromium		

1. 3.5, 4.0mm size 2. 2.25~3.25mm size


Small size added

2.25x33,38mm sizes are added. XIENCE can be used more than ever for the treatment of small vessels.

AMI


Short DAPT

XIENCE shows lower long term ST rates in STEMI EXAMINATION



Sabate M et al. Lancet. 2012 Oct 27; 380(9852): 1482- 90.


XIENCE is associated with vascular healing in STEMI patients MECHANISM AMI (OCT)



Morino Y et al. Cardiovasc Interv Ther. 2018 Jan 9.


XIENCE protects patients 0% ST with 3 month DAPT discontinuation

STOP DAPT
In a multicenter, single-arm trial in patients judged to be suitable for 3-month DAPT after PCI




Natsuaki M et al. Cardiovasc Interv Ther. 2016 Jul ; 31 3 : 196 - 209

XIENCE is associated with vascular healing in stable angina patients MECHANISM Elective (OCT)




Shinke T, MECHANISM- Elective 1 and 3M , ESC 2016



Complex


Polymer Technology

PCI result of the patient with chronic total occlusion PRISON IV



Teeuwen K et al. JACC Cardiovasc Interv. 2017 Jan 23 ;10 2 : 133-143.


PCI and CABG results of the patient with left main lesion EXCEL



Stone GW et al. N Engl J Med. 2016 Dec 8 ; 375 23 : 2223 - 2235.

Thromboresistance of XIENCE fluoropolymer


XIENCE consistently shows reduced platelet aggregation/activation (thrombus) and inflammation as compared to BP-DES (green: platelets)



Otsuka F, et al : JACC Cardiovasc Interv. 2015 ; 8 : 1248 -1260.

Biological safety of XIENCE fluoropolymer

The distribution of inflammation figures obtained from human bodies one to five years after deploying a stent showed that XIENCE caused lower inflammation than BMS and the first generation DES



Mori H et al, Journal of the American Heart Association 6.11 (2017) : e007244

Ensures coating integrity even at max expansion

XIENCE Sierra coating remains intact at maximum post-dilatation expansion from 3.5mm to 5.5mm

